Molecular and Cellular Biochemistry

, Volume 306, Issue 1–2, pp 19–23 | Cite as

Immediate effect of fluvastatin on lipid levels in acute coronary syndrome

  • Petr Ostadal
  • David Alan
  • Jiri Vejvoda
  • Jana Cepova
  • Jiri Kukacka
  • Peter Blasko
  • Lucia Martinkovicova
  • Jan Vojacek


It is widely assumed that acute benefit of statin therapy is mediated especially by non-lipid effects. The immediate influence of statins on lipid levels in patients with acute coronary syndrome (ACS) is, however, not clear. A total of 64 consecutive patients with ACS were randomized at admission to fluvastatin 80 mg (Group 1, = 32) or standard therapy without statin (Group 2, = 32). The levels of total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), high-density-lipoprotein cholesterol (HDL-C), and triglycerides (TG) were examined at admission and after 24 h. Baseline characteristics were comparable in both groups. In Group 1, fluvastatin significantly decreased the levels of TC by 14.5%, LDL-C by 17.2%, and HDL-C by 10.0% (< 0.001); TG were not influenced. In Group 2 only marginal reductions in TC (by 4.1%, = 0.03) and HDL-C (by 7.5%, < 0.01) were detected; the levels of LDL-C and TG were not changed. As compared with Group 2, in Group 1 the final levels of TC (= 0.02) and LDL-C (= 0.01) were significantly lower. Fluvastatin therapy, when started at admission in patients with ACS, significantly reduces TC and LDL-C already after 24 h. We suggest that the lipid-lowering effect of statins in the therapy of ACS is probably as prompt as non-lipid effects.


Fluvastatin Statin LDL-Cholesterol Cholesterol Acute Coronary Syndrome Myocardial Infarction Unstable Angina Pectoris 


  1. 1.
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) (1994) Lancet 344(8934):1383–1389Google Scholar
  2. 2.
    Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels (1998) The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339(19):1349–1357Google Scholar
  3. 3.
    Sacks FM, Pfeffer MA, Moye LA et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335(14):1001–1009PubMedCrossRefGoogle Scholar
  4. 4.
    Ostadal P, Alan D, Vejvoda J (2005) Statins in the first-line therapy of acute coronary syndrome - similar to aspirin? Exp Clin Cardiol 10(1):9–16Google Scholar
  5. 5.
    Fang CH, Li JJ, Hui RT (2005) Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome. Med Hypotheses 64(1):192–196PubMedCrossRefGoogle Scholar
  6. 6.
    Wolfrum S, Dendorfer A, Schutt M et al (2004) Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44(3):348–355PubMedCrossRefGoogle Scholar
  7. 7.
    Bell RM, Yellon DM (2003) Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41(3):508–515PubMedCrossRefGoogle Scholar
  8. 8.
    Hayashidani S, Tsutsui H, Shiomi T et al (2002) Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105(7):868–873PubMedCrossRefGoogle Scholar
  9. 9.
    Ostadal P, Alan D, Hajek P et al (2003) The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. Mol Cell Biochem 246(1-2):45–50PubMedCrossRefGoogle Scholar
  10. 10.
    Tousoulis D, Antoniades C, Katsi V et al (2005) The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. Int J CardiolGoogle Scholar
  11. 11.
    Macin SM, Perna ER, Farias EF et al (2005) Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J 149(3):451–457PubMedCrossRefGoogle Scholar
  12. 12.
    Ray KK, Cannon CP (2005) Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol 96(5A):54F–60FPubMedCrossRefGoogle Scholar
  13. 13.
    Nair P, Roguin A (2006) Statins and the acute coronary syndrome: ‘the early bird catches the worm’. Int J Clin Pract 60(6):716–727PubMedCrossRefGoogle Scholar
  14. 14.
    Kanadasi M, Cayli M, Demirtas M et al (2006) The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. Heart Vessels 21(5):291–297PubMedCrossRefGoogle Scholar
  15. 15.
    Zhou T, Zhou SH, Qi SS et al (2006) The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta 368(1-2):168–172PubMedCrossRefGoogle Scholar
  16. 16.
    Michelena HI, Osorio LA, Citkowitz E (2005) Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. Int J Cardiol 101(1):111–114PubMedCrossRefGoogle Scholar
  17. 17.
    Marchesi S, Lupattelli G, Siepi D et al (2000) Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 36(5):617–621PubMedCrossRefGoogle Scholar
  18. 18.
    Li JJ, Chen MZ, Chen X et al (2003) Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol 26(10):472–476PubMedCrossRefGoogle Scholar
  19. 19.
    Tsunekawa T, Hayashi T, Kano H et al (2001) Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104(4):376–379PubMedCrossRefGoogle Scholar
  20. 20.
    Kayikcioglu M, Turkoglu C, Kultursay H et al (1999) The short term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction [abstract]. Circulation 100(suppl 1):I-303, Abstract 1586Google Scholar
  21. 21.
    Schwartz GG, Olsson AG, Ezekowitz MD et al (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285(13):1711–1718PubMedCrossRefGoogle Scholar
  22. 22.
    Liem AH, van Boven AJ, Veeger NJ et al (2002) Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 23(24):1931–1937PubMedCrossRefGoogle Scholar
  23. 23.
    Arntz HR, Agrawal R, Wunderlich W et al (2000) Beneficial effects of pravastatin (+/−colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 86(12):1293–1298PubMedCrossRefGoogle Scholar
  24. 24.
    Cannon CP, Braunwald E, McCabe CH et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15):1495–1504PubMedCrossRefGoogle Scholar
  25. 25.
    Thompson PL, Meredith I, Amerena J et al (2004) Effect of pravastatin compared with placebo initiated within 24 h of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J 148(1):e2PubMedCrossRefGoogle Scholar
  26. 26.
    de Lemos JA, Blazing MA, Wiviott SD et al (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292(11):1307–1316PubMedCrossRefGoogle Scholar
  27. 27.
    Briel M, Schwartz GG, Thompson PL et al (2006) Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 295(17):2046–2056PubMedCrossRefGoogle Scholar
  28. 28.
    Hulten E, Jackson JL, Douglas K et al (2006) The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 166(17):1814–1821PubMedCrossRefGoogle Scholar
  29. 29.
    Ostadal P, Alan D, Hajek P et al (2005) Fluvastatin in the therapy of acute coronary syndrome: rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]. Curr Control Trials Cardiovasc Med 6(1):4PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Petr Ostadal
    • 1
    • 2
  • David Alan
    • 1
  • Jiri Vejvoda
    • 1
  • Jana Cepova
    • 3
  • Jiri Kukacka
    • 3
  • Peter Blasko
    • 1
  • Lucia Martinkovicova
    • 1
  • Jan Vojacek
    • 4
  1. 1.Department of CardiologyCharles University in Prague, 2nd Faculty of Medicine & University Hospital MotolPragueCzech Republic
  2. 2.Cardiocenter, Department of CardiologyCharles University in Prague, 3rd Faculty of Medicine & University Hospital Kralovske VinohradyPragueCzech Republic
  3. 3.Department of Clinical Biochemistry and PathobiochemistryCharles University in Prague, 2nd Faculty of Medicine & University Hospital MotolPragueCzech Republic
  4. 4.Department of Cardiac SurgeryCharles University in Prague, 2nd Faculty of Medicine & University Hospital MotolPragueCzech Republic

Personalised recommendations